This review summarizes how LC–MS–based metabolomics is uncovering circulating metabolites that differ years before diagnosis between women who later develop breast cancer and those who remain cancer free, reflecting both lifestyle and endogenous biology. Recent metabolome‑wide association studies in prospective cohorts have identified candidate biomarkers of susceptibility that could one day refine individual risk prediction and enable more personalized prevention strategies. However, most signals still lack robust replication, prompting calls for larger validation studies, subtype‑specific analyses across diverse populations, and broader analytical coverage to fully exploit metabolomics in breast cancer risk stratification.
To learn more Click Here ##Reference## Füreder, Julia et al. Metabolomics-enabled biomarker discovery in breast cancer research Trends in Endocrinology &…
